Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.

PubWeight™: 1.10‹?› | Rank: Top 10%

🔗 View Article (PMID 8959957)

Published in J Am Acad Dermatol on December 01, 1996

Authors

S Tseng1, G Pak, K Washenik, M K Pomeranz, J L Shupack

Author Affiliations

1: Ronald O. Perelman Department of Dermatology, New York University Medical Center, NY 10016, USA.

Articles citing this

Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis (1999) 1.40

Behçet's disease. Arthritis Res Ther (2003) 1.07

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer (2003) 0.98

Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov (2007) 0.92

DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture. Br J Ophthalmol (2002) 0.87

Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J (2003) 0.86

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag (2008) 0.86

Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs (2003) 0.81

Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf (2012) 0.80

Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice. J Biomed Biotechnol (2002) 0.79

What can we learn from the thalidomide experience: an ophthalmologic perspective. Curr Opin Ophthalmol (2011) 0.77

The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol (2008) 0.76

Latanoprost-induced changes in rat intraocular pressure: direct or indirect? J Ocul Pharmacol Ther (2008) 0.76

Systemic and Central Nervous System Vasculitides. Curr Treat Options Neurol (2000) 0.76

Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermatol (2014) 0.75

Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach. Pharmaceuticals (Basel) (2011) 0.75

Thalidomide in dermatology: revisited. Indian J Dermatol (2015) 0.75

Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases. Mol Clin Oncol (2014) 0.75

[Dermatological symptoms in rheumatology]. Z Rheumatol (2008) 0.75

Pimping up drugs. Recovered, superannuated and under exploited drugs - An introduction to the basics of drug reprofiling. Curr Drug Discov Technol (2017) 0.75

Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol (2017) 0.75

Articles by these authors

Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol (1996) 1.45

Inocoterone and acne. The effect of a topical antiandrogen: results of a multicenter clinical trial. Arch Dermatol (1992) 1.41

Status of medical treatment for androgenetic alopecia. Int J Dermatol (1993) 1.39

Six-hour versus 48-hour patch testing with varying concentrations of potassium dichromate. Am J Contact Dermat (1998) 1.38

Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol (1994) 1.23

Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol (1998) 1.14

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol (2000) 1.12

Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol (1991) 1.12

Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol (1997) 1.02

Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception (2001) 0.97

A comparison between Dactylaria gallopava and Scolecobasidium humicola: first report of an infection in a tortoise caused by S. humicola. Sabouraudia (1985) 0.94

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril (2001) 0.90

Treatment of keratoacanthomas with oral 13-cis-retinoic acid. N Engl J Med (1980) 0.90

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol (1998) 0.89

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS (1999) 0.88

Levodopa and melanoma. Neurology (1974) 0.88

Mal de Meleda treated with 13-cis retinoic acid. Arch Dermatol (1979) 0.88

Confluent and reticulated papillomatosis: response to high-dose oral isotretinoin therapy and reassessment of epidemiologic data. J Am Acad Dermatol (1994) 0.88

Ulcers of the leg in thalassemia. Arch Dermatol (1977) 0.87

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol (2001) 0.87

Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet (1997) 0.87

A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a double-blind, placebo-controlled clinical trial. Br J Dermatol (1992) 0.86

The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol (1998) 0.86

Diagnostic high-resolution ultrasound in dermatology. Int J Dermatol (1993) 0.85

Histiocytosis X: treatment with topical nitrogen mustard. J Am Acad Dermatol (1980) 0.84

Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol (1981) 0.83

Histologic demonstration of intradermal spirochetes in a patient with Lyme disease. Am J Med Sci (1984) 0.83

Anti-epiligrin cicatricial pemphigoid in a patient with HIV. J Am Acad Dermatol (1997) 0.82

Guidelines of care for androgenetic alopecia. American Academy of Dermatology. J Am Acad Dermatol (1996) 0.82

The treatment of keratosis palmaris et plantaris with isotretinoin. A multicenter study. J Am Acad Dermatol (1982) 0.82

Bioengineering the hair follicle. Organogenesis (2007) 0.81

Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Int J Dermatol (1998) 0.81

Diagnostic ultrasound in dermatology: current uses and future potential. Cutis (1994) 0.81

Antibody titers to an oxidized thymidine moiety are altered by systemic pharmacotherapy and by ultraviolet B phototherapy. Arch Dermatol Res (1993) 0.79

A role for leukotriene antagonists in atopic dermatitis? Am J Clin Dermatol (2001) 0.78

Azaribine, homocystinemia, and thrombosis. Arch Dermatol (1977) 0.77

A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. J Am Acad Dermatol (1994) 0.77

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol (1998) 0.77

Kaposi's sarcoma. N Engl J Med (2000) 0.75

Syncope associated with liquid nitrogen therapy. Arch Dermatol (1977) 0.75

Three-dimensional imaging for diagnostic ultrasound in dermatology. J Am Acad Dermatol (1993) 0.75

Ocular side effects of the retinoids. Int J Dermatol (1989) 0.75

Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol (1998) 0.75

Treatment of dermatophytoses II: Newer topical antifungal drugs. Int J Dermatol (1993) 0.75

Dose-response study of topical minoxidil in male pattern alopecia. J Am Acad Dermatol (1987) 0.75

New York University therapeutic roundtable: a panel of experts answer questions on the treatment of challenging cases. Cutis (1994) 0.75

Evaluation of overland flow model for a hillslope using laboratory flume data. Water Sci Technol (2013) 0.75

Adverse hepatic reactions associated with etretinate in patients with psoriasis--analysis of 22 cases. Ann Acad Med Singapore (1988) 0.75

Acanthosis nigricans-like hyperpigmentation secondary to triazinate therapy. Arch Dermatol (1985) 0.75

Response of psoriatic nails to the aromatic retinoid etretinate. Arch Dermatol (1983) 0.75

The glucagonoma syndrome. J Dermatol Surg Oncol (1978) 0.75

Distributed modelling of urban runoff using a meta-channel concept. Water Sci Technol (2010) 0.75

Allergic contact dermatitis due to N,N-dimethyl-para-phenylenediamine in bacteriology technicians. Cutis (1978) 0.75

A concise guide to topical sunscreens: state of the art. Int J Dermatol (1992) 0.75

Systemic drugs in the treatment of dermatophytoses. Int J Dermatol (1993) 0.75

Infantile perianal pyramidal protrusions identified in adult women. J Eur Acad Dermatol Venereol (2014) 0.75

Human skin reaction to ethylene oxide. J Lab Clin Med (1981) 0.75

Physician drug dispensing. J Am Acad Dermatol (1988) 0.75

Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol (1992) 0.75